Pcn166 Economic Evaluation of Anticancer Drugs: A Systematic Review on Cost-Effectiveness Studies Based on Healthcare System Claims Databases

Abstract

We developed a partitioned survival model to reflect the disease progression and treatment pattern of NSCLC with three health states, referring to progression-free survival, post-progression survival, and death. The proportion of patients in each state was estimated based upon parametric survival equations. Clinical efficacy data was extracted from trial ARCHER1050. Costs and utilities for each line of treatments were generated from publications. A discount of 3% per year was applied. Qualityadjusted life-years (QALYs) were used as the primary health outcome. The health outcome of QALY and the incremental cost effectiveness ratio (ICER) were calculated. One-way sensitivity and probabilistic sensitivity analyses were conducted to test the uncertainty of the model. Results: In the base-case scenario, dacomitinib resulted in a gain of 0.